Department of General Practice, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China; Department of General Practice, Kongjiang Community Health Service Center, Yangpu District, Shanghai 200093, China.
Department of Pediatrics, Fourth People's Hospital Affiliated to Tongji University, Shanghai 200434, China.
Int Immunopharmacol. 2022 Jun;107:108711. doi: 10.1016/j.intimp.2022.108711. Epub 2022 Mar 25.
Podocyte pyroptosis is an inflammatory form of cell death associated with Diabetic nephropathy (DN). It is reported that hyposialylated Angiopoietin-like-4 (Angptl4) secreted by glomerular podocytes plays an important role in the formation of proteinuria. Previous study indicated that supplementation of sialic acid precursor N-acetylmannosamine (ManNAc) could inhibit podocyte apoptosis and actin cytoskeleton rearrangement. Nevertheless, whether ManNAc could improve diabetic kidney damage by inhibiting podocyte pyroptosis remains unclear. This study aimed to explore the effect of ManNAc therapy on alleviating diabetic renal injury and podocyte pyroptosis, and its possible mechanism was also figured out. The male 8-week-old C57BL/6 mice were divided into three groups: control group, Streptozocin (STZ)-induced DN group, and ManNAc treated diabetic group. Then, the changes in renal function, renal histopathology, podocyte pyroptosis, reactive oxygen species (ROS), and mitochondrial dysfunction were measured. Herein, we observed that the upregulated expression of Angptl4 was involved in podocyte injury. ManNAc treatment ameliorated podocyte ultrastructure, renal function, and renal histopathology in STZ-induced DN mice. In addition, ManNAc administration attenuated podocyte cell death and suppressed the activation of Nucleotide leukin-rich polypeptide 3 (NLRP3), caspase-1, and interleukin-1β (IL-1β), and the cleavage of gasdermin-D (GSDMD). Moreover, ManNAc inhibited ROS production and restored mitochondrial morphology in vivo and vitro. Further, ManNAc administration significantly alleviated podocyte pyroptosis through inhibiting ROS/NLRP3 signaling pathway. Therefore, these results elucidated that the upregulated expression of Angptl4 was involved in podocyte injury and ManNAc treatment protected against podocyte pyroptosis via inhibiting mitochondrial injury and ROS/NLRP3 signaling pathway in DN mice.
足细胞细胞焦亡是与糖尿病肾病(DN)相关的一种炎症形式的细胞死亡。有报道称,肾小球足细胞分泌的低唾液酸化血管生成素样蛋白 4(Angptl4)在蛋白尿形成中发挥重要作用。先前的研究表明,唾液酸前体 N-乙酰甘露糖胺(ManNAc)的补充可以抑制足细胞凋亡和肌动蛋白细胞骨架重排。然而,ManNAc 是否可以通过抑制足细胞细胞焦亡来改善糖尿病肾脏损伤仍不清楚。本研究旨在探讨 ManNAc 治疗对缓解糖尿病肾脏损伤和足细胞细胞焦亡的作用及其可能的机制。将雄性 8 周龄 C57BL/6 小鼠分为三组:对照组、链脲佐菌素(STZ)诱导的糖尿病肾病组和 ManNAc 治疗糖尿病组。然后,测量肾功能、肾脏组织病理学、足细胞细胞焦亡、活性氧(ROS)和线粒体功能障碍的变化。在此,我们观察到 Angptl4 的上调表达参与了足细胞损伤。ManNAc 治疗改善了 STZ 诱导的糖尿病肾病小鼠的足细胞超微结构、肾功能和肾脏组织病理学。此外,ManNAc 给药可减少足细胞细胞死亡,并抑制核苷酸结合寡聚结构域样受体热蛋白结构域相关蛋白 3(NLRP3)、半胱天冬酶-1 和白细胞介素 1β(IL-1β)的激活,以及天冬氨酸特异性半胱氨酸蛋白酶 3(caspase-3)的切割。此外,ManNAc 在体内和体外抑制 ROS 产生并恢复线粒体形态。进一步研究表明,ManNAc 通过抑制 ROS/NLRP3 信号通路显著减轻足细胞细胞焦亡。因此,这些结果表明,Angptl4 的上调表达参与了足细胞损伤,ManNAc 治疗通过抑制线粒体损伤和 ROS/NLRP3 信号通路来保护糖尿病肾病小鼠的足细胞细胞焦亡。